Form 4: Ionis Pharma EVP Sells Shares After Strong PRSU Vesting

Ionis Pharmaceuticals' EVP, Chief Business Officer Joseph Baroldi, sold 5,296 shares of common stock after vesting of performance-based restricted stock units.

Summary

• Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals Inc. (IONS), acquired 10,278 shares of common stock on January 29, 2026, at a price of $0.0.
• These shares were earned upon the vesting of performance-based restricted stock units (PRSUs) granted on January 18, 2023.
• The Compensation Committee certified that the pre-established performance goal, based on the Issuer's relative total shareholder return compared to a peer group, was achieved at a level resulting in a vest of 167.27% of target shares.
• On January 30, 2026, Mr. Baroldi disposed of 5,296 shares of common stock at a weighted average price of $82.9615 per share, with individual transactions ranging from $82.95 to $82.97.
• Following these transactions, Mr. Baroldi directly owns 45,413 shares and indirectly owns 4,772 shares through his spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral event. While there is an insider sale, it follows a strong achievement of performance-based equity vesting, reflecting positive past company performance relative to peers.

Positives

• Performance-based restricted stock units (PRSUs) vested at 167.27% of target shares, indicating strong achievement of pre-established performance goals based on relative total shareholder return compared to a peer group.

Negatives

• An executive insider sale of 5,296 shares, even following a vesting event, could be perceived as a slight negative signal by some investors.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales following the vesting of equity compensation like PRSUs, are common occurrences. These transactions often relate to tax obligations, personal financial planning, or portfolio diversification rather than a change in the executive's outlook on the company's future prospects.

Comparison to Industry Standards

• This filing details an individual executive's stock transactions, which are not typically benchmarked against industry-wide operational or financial standards.
• The performance-based restricted stock units (PRSUs) vested at 167.27% of target, indicating strong relative total shareholder return compared to a peer group, as certified by the Compensation Committee. This level of achievement suggests the company's performance metrics were robust within its competitive landscape during the performance period.

Stakeholder Impact

• Shareholders may note the insider sale, but the underlying vesting of PRSUs at a high percentage (167.27%) suggests strong company performance relative to its peer group, which could be viewed positively.

Key Dates

Recommendation

The transaction reflects a routine event where an executive monetizes vested performance-based equity. While there's an insider sale, it follows a strong performance achievement (167.27% of target PRSUs), suggesting past operational success. This single event does not provide sufficient new fundamental information to alter a prior investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, insider trading, stock sale, PRSU, executive compensation